Kornimate/medical-research-clean huggingface dataset:
increasing colorectal cancer (crc) screening in primary care

Conditions: Colorectal Cancer Screening

Summary: colorectal cancer screening remains lower than optimal. the purpose of this study was to test the efficacy of phone-based motivational interviewing versus tailored communication versus usual care in increasing crc screening in primary care clinics.

regular screening reduces both morbidity and mortality from colorectal cancer (crc). screening rates, however, remain low suggesting the need for innovative research designed to increase screening behavior. the purpose of this study is to compare the effectiveness of two interventions (tailored health communication \[thc\] and motivational interviewing \[mi\]) in increasing crc screening behavior. both interventions are based on a strong conceptual framework derived from the health belief model (hbm) and transtheoretical model (ttm), allowing us to explore the underlying mechanisms through which these interventions impact behavior change. the primary aim of this study is to compare crc screening test use among 804 participants randomly allocated to control or intervention conditions; participants will be recruited from the two sites (chicago, il, and nashville, tn). the 3 study groups will receive (1) standard care, (2) tailored health communication, and (3) motivational interviewing. eligibility criteria for study participants includes being 50 years or older, not having crc, and being of average or moderate risk for crc. study participants will be surveyed by telephone about crc-related beliefs pre-intervention (time 1), 1 month postintervention (time 2), and at 6 months postintervention (times 3 and 4, respectively). dichotomous behavioral outcomes (had screening test or not) and stages of crc screening test adoption (based on the ttm) will be assessed, as well as sociodemographic and belief predictors of screening behavior. binomial and multinomial logistic regression models will be used to evaluate screening test use and stage of test adoption. sociodemographic and belief variables will be used as covariates, with intervention group as the primary independent predictor. descriptive statistics and anova will be employed to assess between intervention differences in amenable beliefs. path (mediation) analysis will be performed to further explore the underlying mechanisms through which thc and mi may differentially affect crc screening behavior.

Eligibility criteria:
inclusion criteria: * all genders * can speak, read, write english * no diagnosis of colorectal cancer * non-adherent with screening * age 50 or older exclusion criteria: * had colorectal cancer * adherent with screening

Keywords: colorectal cancer screening tailored education motivational interview patient education
ct prediction for transcatheter tricuspid interventions

Conditions: Tricuspid Regurgitation; Computed Tomography

Summary: the aim of this study is to enhance the predictability of therapeutic success in transcatheter tricuspid valve intervention (ttvi) for patients with severe tricuspid regurgitation (tr). this will be achieved through automated analyses of pre-interventional computed tomography (ct) scans. severe tricuspid regurgitation is associated with poor patient outcomes. in advanced stages, pharmacological therapy becomes ineffective, and surgical intervention carries a high mortality risk. given this clinical challenge, catheter-based treatment of the tricuspid valve has become a focal point of research. one well-established treatment strategy is percutaneous tricuspid valve intervention, which aims to reduce regurgitation either through annuloplasty, leaflet-based edge-to-edge repair or valve replacement. this approach has been shown to significantly decrease the severity of regurgitation, leading to a dramatic reduction in symptom burden and a marked improvement in quality of life. however, predicting which patients will benefit most from ttvi and determining the optimal technique for each individual remain largely unresolved challenges. artificial intelligence (ai)-powered software, such as heart.ai by laralab (munich), enables automated measurement of anatomical structures captured via ct imaging. this technology already allows for rapid and precise assessment of cardiac chambers and the tricuspid annulus throughout the entire cardiac cycle, facilitating a comprehensive three-dimensional evaluation of right heart anatomy. to refine patient selection and optimize procedural strategies for tr treatment, the researcher work a multi-center collaboration to analyze treatment outcomes and patient response to specific therapeutic approaches.


Eligibility criteria:
inclusion criteria: * the patient underwent full cycle cardiac computed tomography for analysis of valvular heart disease * a transcatheter tricuspid valve intervention is performed * the patient is 18 years or older exclusion criteria: * none

Keywords: transcatheter tricuspid valve intervention ttvi tr msct tricuspid regurgitation
the effects of rtms in rehabilitation following spinal cord injury

Conditions: Spinal Cord Injury; Rehabilitation; Transcranial Magnetic Stimulation; Neurorehabilitation

Summary: the project will investigate whether repetitive transcranial magnetic stimulation (rtms) can be used to potentiate/prime spinal cord injured patients' nervous systems for more intense rehabilitation exercise of longer duration - thus leading to greater recovery of motion function. the technique, in which a magnetic coil is positioned above the scalp and forms a magnetic field that activates the desired center of the brain (eg motor cortex), is used in clinical practice for the treatment of a number of disorders. however, although a combination of rtms and gait training in sci patients previously has proven beneficial, it is unknown whether additional functional gains can be achieved by combining rtms and supervised, high-intensity resistance training. in this project, 30 newly-admitted patients will be recruited and randomized to receive either active rtms and strength training (n = 15) or sham (imitated) rtms + strength training, in parallel with standard care. the investigators hypothesize that the active rtms group will have superior gains in locomotor function and muscle mass, compared to the sham group.


Eligibility criteria:
inclusion criteria: * sub-acute (\<6 months) incomplete spinal cord injury * admitted at the sciwdk for primary rehabilitation exclusion criteria: * medical history of multiple central nervous system lesions, * severe structural, * inflammatory or degenerative cerebral disorders, * epilepsy, * other neurological diseases, * lower limb peripheral injury, * or orthopedic injuries that may limit maximal effort contractions
efficacy and safety of prehospital administration of bivalirudin in stemi patients

Conditions: Acute Myocardial Infarction

Summary: the purpose of this study is to describe the efficacy and safety of prehospital administration of bivalirudin, as a substitute for heparin, in patients with acute myocardial infarction redirected for primary angioplasty bypassing local hospitals, immediately after the diagnosis is confirmed via tele-transmission of a 12-lead electrocardiogram.

primary angioplasty (ppci) is the therapy of choice in patients with st elevation acute myocardial infarction (stemi) in denmark. however, time is lost transferring patients from a local hospital to an invasive treatment centre. time can be saved by redirecting stemi patients to ppci based on wireless prehospital 12-lead electrocardiogram (ecg) transmission directly to a cardiologist's handheld device. to prevent complications during the transportation of stemi patients to the invasive hospital, patients are treated with oxygen, aspirin, clopidogrel, heparin, and nitro-glycerine in the ambulance. however, heparin use is cumbersome for the ambulance personnel since it must be kept at 5 degrees celsius. an alternative to heparin may be bivalirudin, since it can be kept at room temperature and thus is easily administered in the prehospital setting. comparison: heparin versus bivalirudin treatment. efficacy is determined by thrombolysis in myocardial infarction (timi) flow in the first and final coronary angiogram. safety is determined by the rate of bleeding complication.

Eligibility criteria:
inclusion criteria: * st elevation acute myocardial infarction patients redirected for primary angioplasty * symptoms less than 12 hours exclusion criteria: * contraindications against primary angioplasty

Keywords: bivalirudin heparin bleeding timi flow stemi
neuraxial and neurolytic analgesia for intractable pain

Conditions: Pain

Summary: the purpose of this study is to collect longitudinal data on outcomes of neuraxial or neurolytic procedures in patients with intractable cancer and chronic noncancer pain so that we may contribute to the growing evidence for or against these therapies and to provide data for ongoing quality improvement activities.


Eligibility criteria:
inclusion criteria: * treated for intractable pain by the uw interventional pain treatment program * inpatient or outpatient exclusion criteria: * less than 18 years of age
the effect of foot reflexology in intensive care nurses

Conditions: Fatigue; Pain; Stress; Nurse

Summary: this study was planned as a randomized controlled experimental research design to examine the effect of foot reflexology applied to nurses working in the intensive care unit on stress, fatigue and low back pain.

the universe of the research consisted of a total of 90 nurses working in a university and a public hospital in a city. among the nurses, those who meet the criteria for inclusion in the study will form the sample. assignment to the intervention and control group will be determined in the computer environment using a simple randomization method (www.randomizer.org/). the number of samples was determined using power analysis. it was decided to recruit a total of 42 nurses, 21 for each group.

Eligibility criteria:
inclusion criteria: * -intensive care unit nurse * those aged 18 to 65 years * working in intensive care for at least 6 months * back pain for at least 3 months * not pregnant, non-breastfeeding * having a regular menstrual cycle * vascular disease and foot fracture, wound, scar, skin damage etc. no situation * volunteered to participate in the research * not using antidepressants, sleeping pills, etc. exclusion criteria: * working in intensive care for less than 6 months * no chronic low back pain * pregnant, lactating * do not have a regular menstrual cycle * vascular disease and foot fracture, wound, scar, skin damage etc. situation found * using antidepressants, sleeping pills, etc.
effectiveness of tranexamic acid when used as an adjunct to misoprostol for the treatment of postpartum hemorrhage

Conditions: Postpartum Hemorrhage

Summary: this study is a randomized, double-blind, placebo controlled trial that will enroll 250 women (125 per study arm). the objective of the study is to determine the efficacy and tolerability of oral tranexamic acid when used as an adjunct to misoprostol for treatment of postpartum hemorrhage (pph). women will be diagnosed with postpartum hemorrhage if blood loss reaches 700ml in the calibrated receptacle. if diagnosed with postpartum hemorrhage , the woman will be randomized to receive either tranexamic acid or placebo, both in tablet form. all participants will receive 800 mcg sublingual misoprostol (4 tablets 200mcg each). the investigators hypothesize that tranexamic acid (in tablet form) as an adjunct to misoprostol will be more effective than misoprostol alone in stopping postpartum bleeding without recourse to further treatment in significantly more women.


Eligibility criteria:
inclusion criteria: * women who delivery vaginally * women who experience pph defined as blood loss ≥700ml * women capable of giving consent exclusion criteria: * clear contraindication for tranexamic acid such as known allergy or thromboembolic event during pregnancy * women delivering via cesarean section * provider feels that the woman, at presentation for delivery, is not in a position to give appropriate informed consent
vibrotactile coordinated reset (vcr): a treatment for early stage parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of our study is to evaluate vibrotactile coordinated reset stimulation (vcr) and its effects on early stage parkinson's symptoms. vcr will be administered with a device called the stanford glove. vcr is expected to provide patients with a non-invasive alternative to the most widely used treatments such as levodopa and or deep brain stimulation. patients will be followed for two years.


Eligibility criteria:
inclusion criteria: 1. ages 18 and older 2. idiopathic parkinson's disease hoehn and yahr stage i 3. fluent in english 4. appropriate social support if required during an off state. 5. comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes. 6. feels comfortable going off pd related medication during in person study visits 7. lives in the united states exclusion criteria: 1. any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies 2. any current drug or alcohol abuse. 3. participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. any other trial participation should be approved by the principal investigators. 4. pregnancy, breast-feeding or wanting to become pregnant 5. physical limitations unrelated to pd that would affect motor ratings 6. craniotomy 7. brain surgery 8. patient is unable to communicate properly with staff (i.e., severe speech problems) 9. excessive drooling 10. a type of hair style that would impede the use of an eeg cap 11. sensory abnormalities of the fingertips 12. nasal dysfunction unrelated to smell loss
acute renal insufficiency (ari) rate and predictive score of ari in hospitalized patients for acute coronary syndrome with st-segment elevation needing urgent coronarography

Conditions: Acute Renal Insufficiency; Acute Coronary Syndrome

Summary: the primary objective of the study aims to evaluate frequence of acute renal insufficiency in patients with st-segment elevation who need urgent coronary angiography in ambroise paré hospital. the secondary objectives are: * identify factors of risks associated with the occurrence of acute renal insufficiency after coronarography. * establish a preprocedure score, predicting of acute renal insufficiency after urgent coronary angiography in patients with st+ acute coronary syndrome.


Eligibility criteria:
inclusion criteria: * patient aged ≥ 18 years; * evocative symptoms of myocardiac ischemia: typical chest pain; st-segment elevation and 1 mm in two consecutive peripheral leads and 2 mm in two consecutive precordial derivations, or appearance of a bloc of left branch of novo; * need urgent coronarography; * covered by french social security scheme included cmu. exclusion criteria: * dialysed patient for chronic renal insufficiency; * cardio-resporatory arrest; * cardiogenic choc state; * prior emergency passage to hospital; * patient under tutor, gardianship; * patient covered by french ame scheme; * pregnant women or breastfeeding; * all medical, psychological or social situation which should influents the compliance to protocol according to investigator; * patient refusal.

Keywords: acute renal insufficiency acute coronary syndrome
heart rate variability in children and adolescents with cystic fibrosis

Conditions: Cystic Fibrosis in Children

Summary: this study aims to assess the effects of a resistance exercise training program on heart rate variability in a group of children and adolescents with cystic fibrosis. the study design is a randomized controlled trial.

a randomized controlled study will be carried out in children diagnosed with cystic fibrosis aged 6 to 18 years. individuals will be divided into two groups: control group (con) and strength training (st). heart rate variability will be analyzed using kubios and measured using a suunto watch, with subjects in lying position without movements or speaking for 5 minutes. patients in the st group will complete an individualized guided strength program for 8 weeks (3 sessions of 60 min/week). training prescription will be individualized and based on the 5 repetition maximum test (60-80%). upper and lower limbs exercises will be used, including seated bench press, seated lateral row and leg press. outcome measures will be performed at baseline and after 8 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of cystic fibrosis * age between 6 and 18 years old * mild to moderate lung function levels * signature of the informed consent form by legal guardian and patient. exclusion criteria: * active smoking * exacerbation in the last 3 months * presence of gastrostomy * use of beta-blocker drugs * diagnosed heart disease * alterations in the locomotor system

Keywords: cystic fibrosis heart rate variability exercise
rilonacept in diabetes mellitus type 1: safety study

Conditions: Type 1 Diabetes Mellitus

Summary: this study is being done to see if an investigational drug called rilonacept is safe to use in patients with type 1 diabetes, and if it can slow the loss of the body's ability to secrete insulin in patients who are still able to make a small amount of insulin.


Eligibility criteria:
inclusion criteria: * within 5 years of diagnosis of type 1 diabetes * between the ages of 16 to 45 years * have at least one diabetes-related autoantibody present * have mean c-peptide level \> 0.2 nmol/l on a mixed meal tolerance test * be taking insulin * complete written informed consent exclusion criteria: * taking inhaled or oral steroids (for example advair, orapred) * have an active infection * have serologic evidence of hiv, hepatitis c, hepatitis c, or tuberculosis * have ongoing use of medications known to affect glucose tolerance * have a live vaccine 90 days prior to, or during this study * taking any other experimental medication within the past 28 days * have prior treatment with rilonacept * have any complicating medical issues or abnormal clinical laboratory blood counts or results that interfere with study conduct; history of malignancies * pregnant or lactating females * males and females unwilling to use an acceptable method of contraception for the duration of the study

Keywords: interleukin 1 type 1 diabetes mellitus rilonacept arcalyst
rabeprazole extended-release 50 mg vs. ranitidine 150 mg for maintenance of healed erosive gastroesophageal reflux disease (gerd)

Conditions: Gastroesophageal Reflux Disease (GERD)

Summary: the purpose of this study is to compare the efficacy of rabeprazole extended release (er) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (egerd).

this is a multicenter, randomized, double-blind, double-dummy, parallel-group study. subjects who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups, rab er 50 mg (once daily) or ranitidine 150 mg (twice daily).

Eligibility criteria:
inclusion criteria: 1. prior completion of study e3810-g000-301 or -303. subjects will need to have healed erosive esophagitis (absence of esophageal mucosal breaks or erosions) confirmed by egd and sustained resolution of heartburn at visit 4 or 5 of study e3810-g000-301 or -303. exclusion criteria: 1. esophageal motility disorders (achalasia, scleroderma, or esophageal spasm). 2. barrett's esophagus or esophageal stricture. 3. use of prescription or non-prescription proton pump inhibitors (ppis), histamine receptor antagonists (h2ra), antacids, sucralfate, misoprostol, prokinetics or drugs with significant anticholinergic effects throughout the study. 4. subjects who require chronic use of nonsteroidal anti-inflammatory drugs (nsaids), oral steroids (\>= 20 mg/day prednisone or equivalent), or aspirin (-\>; 325 mg/day). 5. significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular system abnormalities that would be likely to interfere with the conduct of the study, the interpretation of study results, or the health of the subject during the study. 6. any condition that would make the subject, in the opinion of the investigator or sponsor, unsuitable for the study.

Keywords: gastroesophageal reflux disease gerd
impact of probiotic preparation vsl#3 on infants colics

Conditions: Infant Colics

Summary: infantile colic is one of the most commonly reported medical problems within the first three months of life causing appreciable distress for both parents and pediatricians. it appears that multiple independent origins might be involved: amongst them infant's difficult temperament, inadequate mother-infant communication or maternal anxiety, transient lactase deficiency, exposure to cow's milk, abnormal gastrointestinal function, maternal smoking during pregnancy or after delivery. consequently, various treatment approaches have been tried to alleviate this condition. recent studies have suggested that changes of intestinal microflora of a newborn may play an important role in pathogenesis of infantile colic. therefore, dietary supplementation with probiotics has been proposed for the improvement of this condition.

aim of the study is to evaluate the improvement of colics symptoms by the oral administration of vsl#3 and the difference in the daily average crying time (measured with parental diary) between end of treatment and baseline. in this study, 62 infants will be enrolled and will receive 10 drops per day of vsl#3 or placebo according to randomization list. the study product will be supplied as a box containing the oil bottle and a powder stick. the product should be stored refrigerated. on the first day of supplementation, the mother will open the sachet, pour the contents into the bottle and shake vigorously. a dropper is provided to count the drops. the suspension must be shaken vigorously before every use. compliance will be monitored by filling out a diary.

Eligibility criteria:
inclusion criteria: * infants aged between 30 and 90 days * breast fed exclusively during length of trial * diagnosis of infantile colic according to wessel's criteria i.e paroxysmal fussing in infancy for more than three hours per day, at least three days per week but not treated previously for colics. * debut of colic symptoms 6+/-1 days before randomization * written informed consent from one or both parents * stated availability and reliability throughout the study period. exclusion criteria: * major chronic disease * gastrointestinal disease * administration of antibiotics the week before randomization * administration of probiotics two weeks before randomization * infants with gi malformation, cystic fibrosis, other genetic diseases * participation in other clinical trials.

Keywords: colics